Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn as Executive Clinical and Regulatory Lead
Key Points for Investors
- Former FDA Commissioner Dr. Stephen M. Hahn joins Turn Therapeutics as Executive Clinical and Regulatory Lead, a high-profile appointment bringing significant clinical, regulatory, and industry expertise to the company.
- Dr. Hahn will oversee clinical and regulatory strategy for GX-03, Turn’s lead investigational topical therapy for moderate-to-severe atopic dermatitis (eczema), currently in Phase 2 clinical trials.
- Personal commitment to dermatology: Dr. Hahn has direct, personal experience with atopic dermatitis, reinforcing the authenticity and drive behind his commitment to this therapeutic area.
- GX-03 is a first-in-class, non-systemic topical cytokine-modulating therapy designed to address multiple inflammatory pathways, with topline Phase 2 results expected in mid-2026.
- Potential price-sensitive impact: The appointment of a former FDA Commissioner and the upcoming clinical milestones for GX-03 could be significant catalysts for Turn Therapeutics’ share price.
Detailed Article
Westlake Village, Calif., May 18, 2026 — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing targeted and localized therapies for inflammatory skin diseases, has announced the appointment of Dr. Stephen M. Hahn, M.D., as the company’s new Executive Clinical and Regulatory Lead.
Strategic Appointment of Dr. Stephen M. Hahn
Dr. Hahn is a renowned physician-scientist and the former Commissioner of the U.S. Food and Drug Administration (FDA), bringing decades of leadership experience across clinical medicine, regulatory science, and medical product development. His leadership at the FDA included oversight of both COVID and non-COVID regulatory activities, including therapeutics, vaccines, diagnostics, medical devices, and clinical trials.
Prior to his role at the FDA, Dr. Hahn served in top executive positions at MD Anderson Cancer Center and was involved in biotechnology as CEO-Partner at Flagship Pioneering and CEO of Harbinger Health. He has authored over 220 peer-reviewed scientific publications and is recognized for his expertise in clinical research and medical product development, including topical therapies.
The CEO of Turn Therapeutics, Bradley Burnam, emphasized the unique combination of scientific rigor, regulatory expertise, and genuine compassion for patients that Dr. Hahn brings. Importantly, Dr. Hahn’s interest in inflammatory skin diseases is deeply personal, as his family has been affected by atopic dermatitis, underscoring his commitment to advancing new treatment options.
GX-03: Pipeline and Clinical Progress
The company’s lead asset, GX-03, is a first-in-class, non-systemic, topical cytokine-modulating therapy. It is currently in a Phase 2 randomized controlled trial for moderate-to-severe atopic dermatitis, with topline results anticipated in mid-2026.
GX-03 is designed to stabilize the cutaneous microenvironment and modulate epithelial danger sensing, directly targeting upstream inflammatory signaling pathways (IL-36, IL-4, IL-13, IL-31) rather than relying on systemic immune suppression. This approach could represent a differentiated and potentially safer treatment for patients with moderate-to-severe eczema, where existing therapies often fall short or come with significant systemic side effects.
Implications for Shareholders
- The addition of Dr. Hahn is a significant credibility boost and could accelerate the clinical and regulatory progress of GX-03, potentially improving the likelihood of successful trial outcomes and regulatory approvals.
- Given Dr. Hahn’s personal and professional investment in the field, his involvement may attract additional investor interest and strategic partnerships.
- The anticipated topline Phase 2 results in mid-2026 represent a key upcoming catalyst that could materially impact Turn Therapeutics’ valuation and share price, depending on the data outcome.
- The company’s focus on innovative, precision therapies for inflammatory diseases with high unmet needs positions it well for future growth, especially if GX-03 proves effective and safe.
Forward-Looking Statements
Turn Therapeutics cautions investors that certain statements in the press release are forward-looking, involving inherent uncertainties and risks related to the success of development programs and execution of strategic plans. Investors should review the company’s SEC filings, including the Annual Report on Form 10-K for the period ending December 31, 2025, for a detailed discussion of these risks.
Contact
Investor Relations / Media Contact:
Sasha Damouni
Damouni Group LLC
[email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. The article is based on information provided by Turn Therapeutics Inc. as of May 18, 2026, and may contain forward-looking statements subject to risks and uncertainties.
